Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in ...

Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to ...

Video webcasts from participating companies now available here FRENCHTOWN, NJ / ACCESS Newswire / July 22, 2025 / JTC Team ...

Video webcast now available on-demandBOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: ...